Long non-coding RNAs cover large part of the non-coding information of the human DNA, which represents more than 90% of the whole genome. They constitute a wide and complex group of molecules with more than 200 nucleotides, which generally lack an open reading frame, and are involved in various ways in the pathophysiology of cancer. Their roles in the regulation of gene expression, imprinting, transcription, and post-translational processing have been described in several types of cancer. CASC2 was discovered in 2004 in patients with endometrial carcinoma as a potential tumor suppressor. Since then, additional studies in other types of neoplasia have been carried out, and both mechanisms and interactions of CASC2 in cancer have been better elucidated. In this review, we summarize the current knowledge on the role of CASC2 in the genesis, progression, and clinical management of human cancer.

Long non-coding RNA CASC2 in human cancer / Palmieri, Giuseppe; Paliogiannis, Panagiotis; Sini, Maria Cristina; Manca, Antonella; Palomba, Grazia; Doneddu, Valentina; Tanda, Francesco; Pascale, Maria Rosa; Cossu, Antonio. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 111:(2017), pp. 31-38. [10.1016/j.critrevonc.2017.01.003]

Long non-coding RNA CASC2 in human cancer

Palmieri, Giuseppe;Paliogiannis, Panagiotis
;
Sini, Maria Cristina;Doneddu, Valentina;Tanda, Francesco;Cossu, Antonio
2017-01-01

Abstract

Long non-coding RNAs cover large part of the non-coding information of the human DNA, which represents more than 90% of the whole genome. They constitute a wide and complex group of molecules with more than 200 nucleotides, which generally lack an open reading frame, and are involved in various ways in the pathophysiology of cancer. Their roles in the regulation of gene expression, imprinting, transcription, and post-translational processing have been described in several types of cancer. CASC2 was discovered in 2004 in patients with endometrial carcinoma as a potential tumor suppressor. Since then, additional studies in other types of neoplasia have been carried out, and both mechanisms and interactions of CASC2 in cancer have been better elucidated. In this review, we summarize the current knowledge on the role of CASC2 in the genesis, progression, and clinical management of human cancer.
2017
Inglese
111
31
38
8
www.elsevier.com/locate/critrevonc
Cancer; CASC2; lncRNA; Oncogenesis; Oncosuppressor; Animals; Endometrial Neoplasms; Female; Genes, Tumor Suppressor; Humans; RNA, Long Noncoding; Tumor Suppressor Proteins; Hematology; Oncology; Geriatrics and Gerontology
No
Palmieri, Giuseppe; Paliogiannis, Panagiotis; Sini, Maria Cristina; Manca, Antonella; Palomba, Grazia; Doneddu, Valentina; Tanda, Francesco; Pascale, ...espandi
Long non-coding RNA CASC2 in human cancer / Palmieri, Giuseppe; Paliogiannis, Panagiotis; Sini, Maria Cristina; Manca, Antonella; Palomba, Grazia; Doneddu, Valentina; Tanda, Francesco; Pascale, Maria Rosa; Cossu, Antonio. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 111:(2017), pp. 31-38. [10.1016/j.critrevonc.2017.01.003]
info:eu-repo/semantics/article
1 Contributo su Rivista::1.1 Articolo in rivista
262
9
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/203198
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 67
  • ???jsp.display-item.citation.isi??? 60
social impact